Vaxess Technologies

Key People

• Rachel Sha - Chief Executive Officer
• Michael Schrader - Co-Founder
• Mark Tracy - Chief Technical Officer
• Fiorenzo Omenetto - Co-Founder
• Livio Valenti - Co-Founder, Senior VP of Strategy, BD and Operations
• Kathryn Kosuda - Co-Founder, VP of Research & Development

Assessment

Team

Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with significant backgrounds in life sciences and biotechnology.

The leadership team includes individuals with over 20 years of experience in life sciences, including roles at major biopharma companies like Novartis, Genzyme, and Sanofi. This depth of experience is a significant asset for the company's growth and innovation.

Clinical Need

Aspect: Very Strong
Summary: The MIMIX patch addresses the need for needle-free, shelf-stable vaccine delivery, enhancing accessibility and compliance.

Traditional vaccine delivery methods often require cold chain logistics and can be invasive, leading to reduced compliance. The MIMIX patch offers a needle-free, shelf-stable alternative, potentially increasing vaccination rates and accessibility, especially in low-resource settings.

Competition

Aspect: First mover
Summary: Vaxess is pioneering the microarray patch technology for vaccine delivery, with limited direct competition.

As a first mover, Vaxess has the advantage of setting industry standards and capturing market share. However, it also faces the challenge of educating the market and overcoming regulatory hurdles without established precedents.

Technical Challenge

Aspect: Complex
Summary: Developing a novel drug delivery platform involves significant technical complexities, including ensuring efficacy and safety.

Creating a new drug delivery system requires rigorous testing to ensure it delivers the correct dosage, maintains drug stability, and is safe for widespread use. These challenges necessitate substantial R&D investment and time.

Patent

Aspect: Very Strong
Summary: Vaxess holds strong patents for its MIMIX platform, providing a competitive edge.

Holding robust patents allows Vaxess to protect its intellectual property, preventing competitors from replicating its technology and enabling potential licensing opportunities.

Financing

Aspect: Well-funded
Summary: The company has secured over $90 million in funding from reputable investors.

Significant funding from investors like RA Capital Management and Engine Ventures provides the necessary resources for R&D, clinical trials, and scaling manufacturing capabilities.

Regulatory

Aspect: Running FIH
Summary: Vaxess is conducting first-in-human trials for its MIMIX platform.

Initiating first-in-human trials demonstrates the company's commitment to validating its technology and is a critical step toward regulatory approval and commercialization.

Opportunity Rollup

Odds of Success

3.3

Peak Market Share

3.75

Segment CAGR

2.4%

Market Segment

Drug Delivery Devices

Market Sub Segment

Transdermal Patches

Key Takeaway

Vaxess Technologies is well-positioned to revolutionize vaccine and therapeutic delivery with its MIMIX platform, addressing significant clinical needs and market opportunities, supported by a strong team and substantial funding.